Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation

A Malek1, B Gyorffy, C V Catapano

  • 1Laboratory of Oncoendocrinology, N.N.Petrov Institute of Oncology, Pesochny-2, St Petersburg, Russia. anastasia@malek.com

Cancer Gene Therapy
|April 27, 2013
PubMed

Insights

This study introduces a novel method for multi-gene silencing therapy in cancer treatment. It identifies genes regulated by the same microRNA as optimal targets for enhanced therapeutic efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Therapeutic gene silencing shows promise for cancer treatment but faces challenges due to tumor heterogeneity and dynamic gene expression.
  • Limited clinical translation of gene silencing therapies necessitates innovative approaches for managing gene expression in cancer cells.

Purpose of the Study:

  • To propose and experimentally evaluate a new strategy for designing multi-gene silencing therapies.
  • To identify optimal target gene combinations for small hairpin RNA (shRNA) and small interfering RNA (siRNA)-based gene silencing.

Main Methods:

  • Development of a simplified model for gene expression control.
  • Identification of genes co-regulated by the same microRNA as potential therapeutic targets.
  • Experimental validation of the proposed multi-gene silencing approach.

Main Results:

  • Genes commonly regulated by the same microRNA were identified as optimal targets for shRNA/siRNA-based gene silencing.
  • The study demonstrates the feasibility of targeting multiple genes simultaneously for enhanced therapeutic effects.

Conclusions:

  • The proposed method offers a novel algorithm for selecting target genes in multi-gene silencing therapy.
  • This approach holds potential for developing personalized cancer gene therapies by exploiting microRNA regulatory networks.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Combinatorial Gene Control02:33

Combinatorial Gene Control

Combinatorial gene control is the synergistic action of several transcriptional factors to regulate the expression of a single gene. The absence of one or more of these factors may lead to a significant difference in the level of gene expression or repression.
The expression of more than 30,000 genes is controlled by approximately 2000-3000 transcription factors. This is possible because a single transcription factor can recognize more than one regulatory sequence. The specificity in gene...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...